CoChat

Patient‐reported outcomes in trials of incretin‐based therapies in patients with type 2 diabetes mellitus

Davies, M., Speight, J. · 2012 · Diabetes, Obesity and Metabolism
Cited by 54

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Incretin‐based therapies have a glucose‐dependent mode of action that results in excellent glucose‐lowering efficacy with very low risk of hypoglycaemia, and weight neutrality [dipeptidyl peptidase‐4 (DPP‐4) inhibitors] or weight loss [glucagon‐like peptide‐1 (GLP‐1) receptor agonists], in people with type 2 diabetes mellitus (T2DM). Patient‐reported outcomes (PROs) complement physician evaluations of efficacy and tolerability and offer insights into the subjective experience of using modern diabetes treatments. We conducted a systematic search of clinical trials of the GLP‐1 receptor agonists liraglutide, exenatide and long‐acting exenatide, one of which included the oral DPP‐4 inhibitor sitagliptin as a comparator. No other PRO data for DPP‐4 inhibitors were identified. This review summarizes PRO data from eight clinical trials, the majority of which used the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and/or Impact of Weight on Quality of Life‐Lite (IWQOL‐Lite) to evaluate patient experience. People with T2DM were highly satisfied with modern incretin‐based therapies compared with traditional therapies. Treatment satisfaction (including perceptions of convenience and flexibility) was high and generally higher with GLP‐1 agonists in association with their greater glucose‐lowering efficacy and tendency to facilitate weight loss. Weight‐related quality of life (QoL) also improved in people using incretin therapies. The glycaemic improvements achieved with GLP‐1 receptor agonists, coupled with the low incidence of hypoglycaemia and ability to cause weight loss, seemed to offset potential concern about injections. It is plausible that superior patient‐reported benefits found in clinical trials may translate into improved, clinically meaningful, long‐term outcomes through increased treatment acceptability. Long‐term, prospective data are needed to ascertain whether this is the case in practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2012.01595.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 54

Metadata

Authors
Davies, M., & Speight, J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2012-04-17
Volume
14
Issue
10
Pages
882-892
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2123850120
Cited by
54
References
9
FWCI
5.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patient‐reported outcomes in trials of incretin‐based therapies in patients with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01595.x
The paper
Davies, M., & Speight, J. (2012). Patient‐reported outcomes in trials of incretin‐based therapies in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01595.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.